On a roll, Rigel flags a pos­i­tive PhII for its lead, late-stage drug fos­ta­ma­tinib

Rigel has been hav­ing one of those weeks its in­vestors have been dream­ing of for years.

First the biotech $RIGL, which has had some mixed news to re­port on late-stage stud­ies of their drug fos­ta­ma­tinib, helped in­spire some con­fi­dence on Mon­day by an­nounc­ing that the FDA doesn’t need to have a pan­el re­view ahead of its PDU­FA date.

Score one for the op­ti­mists who read that as a tac­it ac­cep­tance, al­though there are ab­solute­ly no guar­an­tees.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.